Tesamorelin + Ipamorelin 5MG/5MG

This 5MG blend combines tesamorelin — the stabilized 44-amino-acid GHRH analog — with ipamorelin, the selective pentapeptide ghrelin mimetic, for integrated GH-axis research. The combination mirrors a well-established principle in secretagogue physiology: GHRH-receptor activation and ghrelin-receptor activation drive growth hormone release through separate intracellular pathways that converge on the somatotroph, and preclinical literature has long explored their combined versus isolated effects. By formulating both agents at a fixed ratio, this blend lets laboratories run synergy-protocol studies, pulse-pattern comparisons, and receptor-crosstalk experiments with guaranteed dosing consistency across cohorts. It is particularly useful in programs mapping the full architecture of GH regulation, where single-pathway stimulation leaves mechanistic questions unanswered. Both components are analytically verified for identity and proportion within the blend. The 5MG total quantity is calibrated for pilot synergy studies, letting research groups establish whether the dual-pathway approach merits scale-up before committing larger resources. For laboratory research use only. Not for human or veterinary use.